帕罗西汀治疗慢性退行性关节疼痛伴发抑郁状态的研究
|
摘要
研究背景:
疼痛特别是慢性疼痛,不单纯是生理学的感觉问题,也是心理学的复杂情绪表现,这种复杂的生理心理反应,总伴随情绪反应,临床经验表明,慢性疼痛和抑郁症常交织在一起,可以加重、甚至引起抑郁症的发生。
研究目的
本研究需探讨精神、心理因素与慢性疼痛的关系及帕罗西汀(赛乐特)对慢性退行性关节疼痛合并抑郁状态的临床疗效。
研究方法
对228例慢性退行性关节疼痛患者进行Zung氏抑郁症状自评量表(SDS)评分筛选出具有抑郁状态者,在疼痛治疗的基础上加用帕罗西汀片(赛乐特),观察其疼痛视觉模拟评分(VAS)评分、Zung氏抑郁症状自评量表(SDS)评分及生活满意度评分并作临床疗效评价。
研究结果
1、Zung氏抑郁症状自评量表(SDS)标准分=53为抑郁。本次调查SDS=53的人数,合计有71例。所占比例为33.1%(71/228)。
2、这71例中排除妊娠或哺乳者:继发于其他疾病的抑郁;正在采用其他抗抑郁剂治者;具有严重心、肝、肾功能障碍;有脑器质性病变和癫痫;具有严重自杀企图、攻击行为、幻觉、妄想等症状患者,并进入治疗研究最终获得结果的患者为61例。
3、这61例患者按随机数字表法随机分为对照组和帕罗西汀组,分别接受治疗。治疗后,帕罗西汀组及对照组的Zung氏抑郁症状自评量表(SDS)评分、生活满意度评分及疼痛视觉模拟(VAS)评分,均较治疗前明显降低(P＜0.05);但治疗后2,4,6周帕罗西汀组Zung氏抑郁症状自评量表(SDS)评分、生活满意度评分及疼痛视觉模拟(VAS)评分,改善程度均明显优于对照组(P＜0.05)。
4、对照组和帕罗西汀组分别于第6周末评价临床总体疗效。帕罗西汀组总有效率(痊愈率+显著有效率+有效率)为86.67%,对照组总有效率为58.06%。帕罗西汀组明显优于对照组(P＜0.05)。
研究结论
慢性疼痛与精神心理因素相关,对其中具有抑郁情绪的患者使用抗抑郁剂治疗能显著改善精神和躯体两方面症状。
Background
Pain, especially the chronic pain, not only is the feeling of physiology, but also the performance of complex emotions in Psychology. This complex physiological and psychological reaction always appears with emotional responses. Clinical experience shows that chronic pain and depression often intertwines with each other. It can aggravate and even induce the depression.
Objective
This study aims to explore the relationship between psychological factors and chronic pain. Besides it also explore the clinical curative effect of Paroxetine on the chronic degenerative arthritic pains mergered with the depression.
Methods
SDS was used for 228 chronic pain patients and the depressives were screened for study through the result of SDS. On the basis of pain therapy, Paroxetine were given to the subjects and then recorded the scores of VAS, SDS and LSS and evaluated the clinical curative effect.
Results
1. People who have the scores of SDS above 53 were regarded as depressives and the total number of these people was 71 in this investigation, covering 33.1 % ( 71/228) of the whole subjects.
2. These people were eliminated in these 71 cases. They are pregnancy or breastfeeding, secondary depression patients, people who are adopting other antidepressant ,people who with serious heart, liver, kidney disorders, people who suffer from organic brain lesions and epilepsy and people who with severe suicide attempts, aggression ,illusion, and delusion. At last, 61 people suited for this study and produced experimental results
3. These 61 people were randomly divided into two groups-control group and Paroxetine group, according to Random digital form. The two groups accepted therapy respectively .After treatment, the scores of SDS,LSS,VAS in Paroxetine group and control group were lower than before obviously(P<0.05).But after treatment, and two, four and six weeks later, the scores of SDS, LSS, and VAS in Paroxetine group improved more than that of control group significantly(P < 0.05).
4. At the end of the sixth week evaluated the clinical curative effect of control group and Paroxetine group respectively. The total effective rate of Paroxetine group is 86.67 % , while control group is 58.06% . Paroxetine group was vastly superior to the control group (P < 0.05).
Conclusions
Chronic pain is relevant to psychological factors. For patients with depression, antidepressant therapy can significantly improve mental and physical symptoms.
疼痛特别是慢性疼痛,不单纯是生理学的感觉问题,也是心理学的复杂情绪表现,这种复杂的生理心理反应,总伴随情绪反应,临床经验表明,慢性疼痛和抑郁症常交织在一起,可以加重、甚至引起抑郁症的发生。
研究目的
本研究需探讨精神、心理因素与慢性疼痛的关系及帕罗西汀(赛乐特)对慢性退行性关节疼痛合并抑郁状态的临床疗效。
研究方法
对228例慢性退行性关节疼痛患者进行Zung氏抑郁症状自评量表(SDS)评分筛选出具有抑郁状态者,在疼痛治疗的基础上加用帕罗西汀片(赛乐特),观察其疼痛视觉模拟评分(VAS)评分、Zung氏抑郁症状自评量表(SDS)评分及生活满意度评分并作临床疗效评价。
研究结果
1、Zung氏抑郁症状自评量表(SDS)标准分=53为抑郁。本次调查SDS=53的人数,合计有71例。所占比例为33.1%(71/228)。
2、这71例中排除妊娠或哺乳者:继发于其他疾病的抑郁;正在采用其他抗抑郁剂治者;具有严重心、肝、肾功能障碍;有脑器质性病变和癫痫;具有严重自杀企图、攻击行为、幻觉、妄想等症状患者,并进入治疗研究最终获得结果的患者为61例。
3、这61例患者按随机数字表法随机分为对照组和帕罗西汀组,分别接受治疗。治疗后,帕罗西汀组及对照组的Zung氏抑郁症状自评量表(SDS)评分、生活满意度评分及疼痛视觉模拟(VAS)评分,均较治疗前明显降低(P＜0.05);但治疗后2,4,6周帕罗西汀组Zung氏抑郁症状自评量表(SDS)评分、生活满意度评分及疼痛视觉模拟(VAS)评分,改善程度均明显优于对照组(P＜0.05)。
4、对照组和帕罗西汀组分别于第6周末评价临床总体疗效。帕罗西汀组总有效率(痊愈率+显著有效率+有效率)为86.67%,对照组总有效率为58.06%。帕罗西汀组明显优于对照组(P＜0.05)。
研究结论
慢性疼痛与精神心理因素相关,对其中具有抑郁情绪的患者使用抗抑郁剂治疗能显著改善精神和躯体两方面症状。
Background
Pain, especially the chronic pain, not only is the feeling of physiology, but also the performance of complex emotions in Psychology. This complex physiological and psychological reaction always appears with emotional responses. Clinical experience shows that chronic pain and depression often intertwines with each other. It can aggravate and even induce the depression.
Objective
This study aims to explore the relationship between psychological factors and chronic pain. Besides it also explore the clinical curative effect of Paroxetine on the chronic degenerative arthritic pains mergered with the depression.
Methods
SDS was used for 228 chronic pain patients and the depressives were screened for study through the result of SDS. On the basis of pain therapy, Paroxetine were given to the subjects and then recorded the scores of VAS, SDS and LSS and evaluated the clinical curative effect.
Results
1. People who have the scores of SDS above 53 were regarded as depressives and the total number of these people was 71 in this investigation, covering 33.1 % ( 71/228) of the whole subjects.
2. These people were eliminated in these 71 cases. They are pregnancy or breastfeeding, secondary depression patients, people who are adopting other antidepressant ,people who with serious heart, liver, kidney disorders, people who suffer from organic brain lesions and epilepsy and people who with severe suicide attempts, aggression ,illusion, and delusion. At last, 61 people suited for this study and produced experimental results
3. These 61 people were randomly divided into two groups-control group and Paroxetine group, according to Random digital form. The two groups accepted therapy respectively .After treatment, the scores of SDS,LSS,VAS in Paroxetine group and control group were lower than before obviously(P<0.05).But after treatment, and two, four and six weeks later, the scores of SDS, LSS, and VAS in Paroxetine group improved more than that of control group significantly(P < 0.05).
4. At the end of the sixth week evaluated the clinical curative effect of control group and Paroxetine group respectively. The total effective rate of Paroxetine group is 86.67 % , while control group is 58.06% . Paroxetine group was vastly superior to the control group (P < 0.05).
Conclusions
Chronic pain is relevant to psychological factors. For patients with depression, antidepressant therapy can significantly improve mental and physical symptoms.
引文
1.Matthew JB,Rebecca LR,Wayne K,et al. Depression and Pain. Comorbidity Arch Intern Med. 2003,163:2433-2445
2.Hansen GR,Streltzer J. The psychology of pain. Emerg Med Clin North Am.2005,23:339-348
3.Sarton G. A history of science: ancient science through the golden age of Greece. New Tork NY: WW Norton;1952
4.Melzack R,Wall PD. Pain mechanisms: a new theory Science. 1965,150:971—979
5.Gotestam KG. A three-dimensional treatment programme for chronic pain. Acta Psychiatr Scand. 1983,67:209 ~ 217
6.Fordyce W. Behavioral methods in chronic pain and illness. St Louis,Mo:CV Mosby;1976
7.Turk DC. Cognitive-behavioral approach to the treatment of chronic pain patients.Reg Anesth Pain Med. 2003,28:573-579
8.De Pascalis V,Magurano MR,Bellusci A,et al. Somatosensory event-related potential and autonomic activity to varying pain reduction cognitive strategies in hypnosis.Clin Neurophysiol. 2001,112:1475-1485
9.Cornel EB,van Haarst EP,Schaarsberg RW,et al. The effect of biofeedback physical therapy in men with Chronic Pelvic Pain Syndrome Type III. Eur Urol.2005,47:607-611
10.Allen KD. Using biofeedback to make childhood headaches less of a pain. Pediatr Ann. 2004,33:241-245
11.Brown CR. Pain management Biofeedback and relaxation therapy. Pract Periodontics Aesthet Dent. 1997,9:1068
12.van Koulil S,van Lankveld W,Kraaimaat FW,et al. Tailored cognitive-behavioral therapy for fibromyalgia: Two case studies. Patient Education and Counseling. 2008,71(2):308-314
13.Barbaral L,William B,Dearma G,et at. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behavior and Immunity. 2007,21(7):953-961
14.Yu HY,Tang Fl,Kuo BI,et al. Prevalence interference and risk factors for chronie pain among Taiwanese community older people. Pain Manage Nurs. 2006,7(1):2—11
15.Webb AN,Kukuruzovic RH,Catto-Smith AG,et al. Hypnortherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007,(4):CD005110
16.Fishbain DA. Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Med Clin North Amn. 1999,83:737-760
17.Gallagher RM, Verma S, Mossey J. Chronic pain. Sources of late-life pain and risk factors for disability. Geriatrics. 2000,55:40-47
18.Weisberg MB, Clavel AL Jr. Why is chronic pain so difficult to treat?Psychological considerations from simple to complex care. Postgrad Med. 1999,106:141-160
19.Dersh J,Gatchel RJ,Polatin P,et al. Prevalence of psychiatric disorders in patients with chronic work-related musculoskeletal pain disability. J Occup Environ Med.2002,44:459-468
20.Atkinson JH,Slater MA,Patterson TL,et al. Prevalence, onset and risk of psychiatric disorders in men with chronic low back pain: a controlled study. Pain.1991,45:111-121
21.Turner JA,Deyo RA,Loeser JD,et al. The importance of placebo effects in pain treatment and research. JAMA. 1994,271:1609-1614
22.Streltzer J,Eliashof BA,Kline AE,et al. Chronic pain disorder following physical injury. Psychosomatics. 2000,41:227-234
23.Wambach S,Rohr P,Hauser W. Abuse of opioid therapy in somatoform pain disorder A contribution from a psychosomatic / pain therapist point of view to the discussion of the indication of opioids in nonmalignant pain based on 8 cases.Schmerz.2001,15:254-264
24.Ochoa JL.Truths errors and lies around "reflex sympathetic dystrophy" and "complex regional pain syndrome".J'Neurol.1999,246:875-879
25.Abebaw F,Malay A,Girmay M,et al.Utility of the concept of minor depressive disorder:Evidence from a large rural community sample in a developing country setting.J Affective Disorders.2007,104:111-118
26.Koen D,Ronny B,Sing L,et al.Mental disorders among persons with chronic back of neck pain:Results from the world mental health surveys[J].Pain.2007,129:332-342
27.Wilson KG,Chochinov HM,Skirko MG,el al.Depression and Anxiety Disorders in Palliative Cancer Care[J].Pain Symptom Manage.2007,33(2):118-128
28.李力 黄坤 余建等.恶性肿瘤住院患者伴发抑郁的调查.现代预防医学.2006,33(10):1841-1843
29.De Benedittis G,Lorenzetti A,Piefi A.The role of stressful life events in the onset of chronic primay headache[J].Pain.1990,40(11):65-75
30.Edmund K,Lance MM,Christopher E.Gender moderates the association between depression and disability in chronic pain patients[J].European Journal of Pain.2006,10:413-422
31.Fishbain DA,Curler R,Rosomof HL,et al Chronic pain associated depression anti-depressants or consequence of chronic pain A review Clin J Pain 1997,13:117-137
32.Lindsay PG,Wyckof M.The depression pain syndrome and its response to anti-depressants.Psychosomatics.1981,22:571
33.Humag Rx,Lu L Chronic.pain and depression.Zhongguo Linchuang kangfu.2002,6(12):1710-1712
34.马玲 倪家骧.抗抑郁药物治疗慢性疼痛的研究进展.中国全科医学.2008,11:2091-2093
35.Naidu PS,Lichtman AH,Archer CC,et al.NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action[J].European journal of pharmacology.2007,566(3):132-136
36.Myint.Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression[J].Neuroimmunomodulation.2007,14(2):65-71
37.Nery.Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder:adouble-blind,randomized,placebo-controlled study[J].Hum Psychopharmacol.2008,23(2):87-94
38.Pilc A,Chaki S,Nowak G,et al.Mood disorders:regulation by metabotropic glutamate receptors[J].Biochemical Pharmacology.2008,75(5):997-1006
39.Sawynok J,Reid A.Peripheral interactions between dextromethorphan,ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats[J].Pain.2003,102(2):179-186
40.Wang D,Noda Y,Tsunekawa H,et al.Role of N-methyl-D-aspartate receptors in antidepressant-like effects of signal receptor agonist 1-(3,4-dimethoxyphen-ethyl)-4-(3-phenylprophyl)piperazine dihydrochloride(SA—4503)in olfactory bulbectomized rats[J].The Jounal of Pharmacology and Experimental Therapeutics.2007,322(3):1305-1314
41.姜佐宁.现代精神病学.北京 科学出版社.2004:630-631
42.Matsuzawa-Yanaqida K,Narita M,Nakajima M,et al.Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites[J].Neuropsychopharmacology.2008,33(8):1952-1965
43.Onal A,Parlar A,Ulker S.Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain[J].Pharmacology Biochemistry Behavior.2007,88(2):171-178
44.Haderer A,Gerner P,Srinivasa V,et al.Cutaneous analgesia after transdermal application of amitriptyline versus lidocaine in rats.Anesth Analg.2003,96(6):1707-1710
45.Asahi KP,Chiyoda-Ku.Serotonin and noradrenaline reuptake inhibitors in animal models of pain[J].Hum Psychopharmacol.2004,19(1):15-19
46.Dawn A,Marcus MD.Chronic Pain A Primary Care Guide to Practical Management[M].倪家骧,孙海燕,薛富善,译.北京:人民卫生出版社.2005:98
47.Dick IE,Brochu RM,Purohit Y,et al.Sodium channel blockade may contribute to the analgesic efficacy of antidepressants[J].The Journal of Pain.2007,8(4):315-324.
48.Jann MW,Slade JH.Antidepressant agents for the treatment of chronic pain and depression[J].Pharmacotherapy.2007,27(11):1571-1587
49.Li SM,Wu SX,Chen XG.The influence of nervous functional rehabilitation for prozac to treat post-stroke depression state.Xiandai Dangfu.2000,4(6):880
50.赵珲,翟美霞.帕罗西汀在慢性疼痛治疗中的应用.实用药物与临床.2008,11(4):245-246
51.Fassion S,Abbate DG.Quality of life in dependent older adults living at home[J].Arch Gerontol Geriatr.2003,35(1):9-20
52.Hishfeld RMA,Montgomery S A,Kelle M B,et al.Social Functioning in Depression:A Review[J].J Clin Psychiatry.2000,61:268-275
53.王骞 谢守付 姜季妍.认知行为治疗对老年抑郁症病人的生活质量影响研究.医学与哲学(人文社会医学版).2009,30(3):37-38
54.张殿君 王俊刚 耿艳萌 等.临床慢性疼痛患者的社会支持及性格特征调查.中国医学伦理学.2009,22(3):82-83
55.王焕亮 张莉等.老年慢性疼痛的评估与治疗.中华现代内科学杂志.2006,3(6):660-661
56.Stanos S,Houle TT.Multidisciplinary and interdisciplinary management of chronic pain.Phys Med Rehabil Clir.N Am.2006,17:435-450
1.姜佐宁.现代精神病学.北京:科学出版社.2004,89-90
2.Delqado PL.Common pathways of depression and pain 「J」.Journal Clin Psychiatry.2004,65(12):16-9
3.Jaracz J,Ryhakowski J.Depression and pain:novel clinical,neurobiological and psychopharmacological data 「J」.Psychiatriapolska.2005,39(5):937-950
4.何梅 贾霞 陈军等.烧伤后并发抑郁患者下丘脑-垂体-肾上腺轴功能变化的研究.中国康复医学杂志.2007,22(12):1120-1121
5.Neeck G,Riedel W.Neurnmediator and hormonal perturhations in fibromyalgia syndrome:results of chronic stress.Baillieres Clin Rheumatol.1994,8(4):763-75
6.Thor KB,Kirby M,Viktrup.Serotonin and noradrenaline involvement in urinary incontinence,depression and pain:scientific basis for overlapping clinical efficacy from a single drug,duloxetine.Int J Clin Pract.2007,61(8):1349-1355
7.王敏建 况利 李大奇.抗抑郁药物对抑郁模型大鼠海马星形胶质细胞的作用.重庆医科大学学报.2006,04
8.Watkins LR,Milligan ED,Mater SF.Spinal cord glia:new players in pain.Pain.2001,93:201-205
9.Krenz NR,Weaver LC.Nerve growth factor in glia and inflammatory cells of the injured rat spinal cord.J Neurochem.2000,74(2):730-739
10.Zerari F,Karpitskiy V,Krause J,et al.Astroglial distribution of neurokinin-2receptor immunoreactivity in the rat spinal cord[J].Neuroseience.1998,84(4):1233-1246.
11.李卉丽 秦绿叶 万有 等.疼痛研究的新亮点:形胶质细胞.生理科学进展.2003,34(1):45-48
12.Ruan HZ,Li X,Li HT.Effects of morphine and electroacupuncture on substance P level in spinal cord and their relation to pain threshod in rats.J Med Coll PIA.1993,8:79-83
13.Cao YQ,Mantyh PW,Carlson EJ,et al.Primary afferent tachykinins are required to experience moderate to intense pain.Nature.1998,392:390-394
14.Bondy B,Bayhai TC,Minovc,et al.Substance Psenum levels are increased in majordepression:preliminary results.J Biol Psychiatry.2003,53:538-542.
15.Ballet S,Aubel B,Mauborgne A,et al.The novel analgesic cizolir-tine inhibitsthe spinal release of substance P and CGRP in rats.Neuropharmacology.2001,40(4):5782-5891
16.Sun RQ,Lawand N,willis WD.The role of calcitonin gene related peptide(CGRP)in the generation and maintenance of mechanical allodynia and hyperalgesiain rates after intradermal injection of capsaicin.Pain.2003,104(122):2012-2081
17.Zhang L,HOff AO,Wiroalawansa SJ,et al.Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity.Pain.2001,89(223):2652-2731
18.Mathe AA,Agren H,Lindstmm L,et al.Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients Apossible trait marker of major depressive disorder.Neurosci Lett.1994,182(2):138-142
19.Jimenez-Vasquez PA,Salmi P,Ahlenius S,et al.Neuropeptide Y in brains of the Flinders Sensitive Line rat a model of depression Effects of electroconvulsivestimuli and damphetamine on peptide concentrations and locomotion.Behav Brain Res.2000,111:115-123
20.Kim H,Whang WW,Kim HT,et al.Expression of neuropeptide Y and cholecystokinin in the rat brain by chronic mild stress.Brain Res.2003,983(122):2012-2018
21.Heilig M,Zachrisson O,Thorsell A,et al.Decreased cerebrospinal fluid NeuropeptideY(NPY) in patients with treatment refractory unipolar majordepression:preliminary evidence for as sociation with prepro NPY genepolymorphism.J Psychialr Res.2004,38(2):1132-121
22.Davidson JR.A history of the concept of atypical depression[J].Clin Psychiatry.2007,68(3):10-5
23.马玲 倪家骧.抗抑郁药物治疗慢性疼痛的研究进展.中国全科医学. 2008,11:2091-2093
24.Matsuzawa-Yanaqida K,Narita M,Nakajima M,et al.Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites[J].Neuropsychopharmacology.2008,33(8):1952-1965
25.Feria M,Abreu P,Abad F,et al.Relationship between autotomy behaviour and spinal cord monoaminergic levels in rats[J].Pain.1992,48(3):429-437
26.Ting E,Roveroni RC,Ferrari LF,et al.Indirect mechanism of histamine-induced nociception in joint of rats[J].Life Science.2007,81(9):765-771
27.朱毅平.米氮平与阿米替林治疗抑郁症并发慢性疼痛的对照研究.医药导报.2008,27(4):408-411
28.魏贤文 李冬雪 徐大斌.慢性疼痛与抑郁障碍的相关性.中国误诊学杂志.2206,6(23):4556-4557
29.Mantyb PW.Neurobiology of substance P and the NKL receptor.J Clin Psychiatry.2002,63(suppl11):6-10
30.Tahmasebi-Sarvestani A,Tedman R,Goss AN.The influence of experimentallyinduced osteoarthrosis on articular nerve fibers of the sheep temporomandibularjoint.J Qrofac Pain.2001,15(3):206-217
31.Datar P,Srivastava S,Coutinho E,et al.Substance P:structure function and therapeutics.Curt Top Med Chem.2004,4:75-103
32.Blier P,Gobbi G,Haddjeri N,et al.Impact of substance P receptor antagonism on the serotonin and norepinephrine systerns:relevance to the antidepressant/anxiolytic response.J Psychiatry Neurosci.2004,9:208-218
33.欧红霞.慢性疼痛和抑郁症临床及生物学相关研究.国际精神病学杂志.2008,35(3):166-169
34.李永华 王永强等.慢性疼痛治疗的循证医学评价,疼痛2004,12(1):28-32
2.Hansen GR,Streltzer J. The psychology of pain. Emerg Med Clin North Am.2005,23:339-348
3.Sarton G. A history of science: ancient science through the golden age of Greece. New Tork NY: WW Norton;1952
4.Melzack R,Wall PD. Pain mechanisms: a new theory Science. 1965,150:971—979
5.Gotestam KG. A three-dimensional treatment programme for chronic pain. Acta Psychiatr Scand. 1983,67:209 ~ 217
6.Fordyce W. Behavioral methods in chronic pain and illness. St Louis,Mo:CV Mosby;1976
7.Turk DC. Cognitive-behavioral approach to the treatment of chronic pain patients.Reg Anesth Pain Med. 2003,28:573-579
8.De Pascalis V,Magurano MR,Bellusci A,et al. Somatosensory event-related potential and autonomic activity to varying pain reduction cognitive strategies in hypnosis.Clin Neurophysiol. 2001,112:1475-1485
9.Cornel EB,van Haarst EP,Schaarsberg RW,et al. The effect of biofeedback physical therapy in men with Chronic Pelvic Pain Syndrome Type III. Eur Urol.2005,47:607-611
10.Allen KD. Using biofeedback to make childhood headaches less of a pain. Pediatr Ann. 2004,33:241-245
11.Brown CR. Pain management Biofeedback and relaxation therapy. Pract Periodontics Aesthet Dent. 1997,9:1068
12.van Koulil S,van Lankveld W,Kraaimaat FW,et al. Tailored cognitive-behavioral therapy for fibromyalgia: Two case studies. Patient Education and Counseling. 2008,71(2):308-314
13.Barbaral L,William B,Dearma G,et at. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behavior and Immunity. 2007,21(7):953-961
14.Yu HY,Tang Fl,Kuo BI,et al. Prevalence interference and risk factors for chronie pain among Taiwanese community older people. Pain Manage Nurs. 2006,7(1):2—11
15.Webb AN,Kukuruzovic RH,Catto-Smith AG,et al. Hypnortherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007,(4):CD005110
16.Fishbain DA. Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Med Clin North Amn. 1999,83:737-760
17.Gallagher RM, Verma S, Mossey J. Chronic pain. Sources of late-life pain and risk factors for disability. Geriatrics. 2000,55:40-47
18.Weisberg MB, Clavel AL Jr. Why is chronic pain so difficult to treat?Psychological considerations from simple to complex care. Postgrad Med. 1999,106:141-160
19.Dersh J,Gatchel RJ,Polatin P,et al. Prevalence of psychiatric disorders in patients with chronic work-related musculoskeletal pain disability. J Occup Environ Med.2002,44:459-468
20.Atkinson JH,Slater MA,Patterson TL,et al. Prevalence, onset and risk of psychiatric disorders in men with chronic low back pain: a controlled study. Pain.1991,45:111-121
21.Turner JA,Deyo RA,Loeser JD,et al. The importance of placebo effects in pain treatment and research. JAMA. 1994,271:1609-1614
22.Streltzer J,Eliashof BA,Kline AE,et al. Chronic pain disorder following physical injury. Psychosomatics. 2000,41:227-234
23.Wambach S,Rohr P,Hauser W. Abuse of opioid therapy in somatoform pain disorder A contribution from a psychosomatic / pain therapist point of view to the discussion of the indication of opioids in nonmalignant pain based on 8 cases.Schmerz.2001,15:254-264
24.Ochoa JL.Truths errors and lies around "reflex sympathetic dystrophy" and "complex regional pain syndrome".J'Neurol.1999,246:875-879
25.Abebaw F,Malay A,Girmay M,et al.Utility of the concept of minor depressive disorder:Evidence from a large rural community sample in a developing country setting.J Affective Disorders.2007,104:111-118
26.Koen D,Ronny B,Sing L,et al.Mental disorders among persons with chronic back of neck pain:Results from the world mental health surveys[J].Pain.2007,129:332-342
27.Wilson KG,Chochinov HM,Skirko MG,el al.Depression and Anxiety Disorders in Palliative Cancer Care[J].Pain Symptom Manage.2007,33(2):118-128
28.李力 黄坤 余建等.恶性肿瘤住院患者伴发抑郁的调查.现代预防医学.2006,33(10):1841-1843
29.De Benedittis G,Lorenzetti A,Piefi A.The role of stressful life events in the onset of chronic primay headache[J].Pain.1990,40(11):65-75
30.Edmund K,Lance MM,Christopher E.Gender moderates the association between depression and disability in chronic pain patients[J].European Journal of Pain.2006,10:413-422
31.Fishbain DA,Curler R,Rosomof HL,et al Chronic pain associated depression anti-depressants or consequence of chronic pain A review Clin J Pain 1997,13:117-137
32.Lindsay PG,Wyckof M.The depression pain syndrome and its response to anti-depressants.Psychosomatics.1981,22:571
33.Humag Rx,Lu L Chronic.pain and depression.Zhongguo Linchuang kangfu.2002,6(12):1710-1712
34.马玲 倪家骧.抗抑郁药物治疗慢性疼痛的研究进展.中国全科医学.2008,11:2091-2093
35.Naidu PS,Lichtman AH,Archer CC,et al.NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action[J].European journal of pharmacology.2007,566(3):132-136
36.Myint.Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression[J].Neuroimmunomodulation.2007,14(2):65-71
37.Nery.Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder:adouble-blind,randomized,placebo-controlled study[J].Hum Psychopharmacol.2008,23(2):87-94
38.Pilc A,Chaki S,Nowak G,et al.Mood disorders:regulation by metabotropic glutamate receptors[J].Biochemical Pharmacology.2008,75(5):997-1006
39.Sawynok J,Reid A.Peripheral interactions between dextromethorphan,ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats[J].Pain.2003,102(2):179-186
40.Wang D,Noda Y,Tsunekawa H,et al.Role of N-methyl-D-aspartate receptors in antidepressant-like effects of signal receptor agonist 1-(3,4-dimethoxyphen-ethyl)-4-(3-phenylprophyl)piperazine dihydrochloride(SA—4503)in olfactory bulbectomized rats[J].The Jounal of Pharmacology and Experimental Therapeutics.2007,322(3):1305-1314
41.姜佐宁.现代精神病学.北京 科学出版社.2004:630-631
42.Matsuzawa-Yanaqida K,Narita M,Nakajima M,et al.Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites[J].Neuropsychopharmacology.2008,33(8):1952-1965
43.Onal A,Parlar A,Ulker S.Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain[J].Pharmacology Biochemistry Behavior.2007,88(2):171-178
44.Haderer A,Gerner P,Srinivasa V,et al.Cutaneous analgesia after transdermal application of amitriptyline versus lidocaine in rats.Anesth Analg.2003,96(6):1707-1710
45.Asahi KP,Chiyoda-Ku.Serotonin and noradrenaline reuptake inhibitors in animal models of pain[J].Hum Psychopharmacol.2004,19(1):15-19
46.Dawn A,Marcus MD.Chronic Pain A Primary Care Guide to Practical Management[M].倪家骧,孙海燕,薛富善,译.北京:人民卫生出版社.2005:98
47.Dick IE,Brochu RM,Purohit Y,et al.Sodium channel blockade may contribute to the analgesic efficacy of antidepressants[J].The Journal of Pain.2007,8(4):315-324.
48.Jann MW,Slade JH.Antidepressant agents for the treatment of chronic pain and depression[J].Pharmacotherapy.2007,27(11):1571-1587
49.Li SM,Wu SX,Chen XG.The influence of nervous functional rehabilitation for prozac to treat post-stroke depression state.Xiandai Dangfu.2000,4(6):880
50.赵珲,翟美霞.帕罗西汀在慢性疼痛治疗中的应用.实用药物与临床.2008,11(4):245-246
51.Fassion S,Abbate DG.Quality of life in dependent older adults living at home[J].Arch Gerontol Geriatr.2003,35(1):9-20
52.Hishfeld RMA,Montgomery S A,Kelle M B,et al.Social Functioning in Depression:A Review[J].J Clin Psychiatry.2000,61:268-275
53.王骞 谢守付 姜季妍.认知行为治疗对老年抑郁症病人的生活质量影响研究.医学与哲学(人文社会医学版).2009,30(3):37-38
54.张殿君 王俊刚 耿艳萌 等.临床慢性疼痛患者的社会支持及性格特征调查.中国医学伦理学.2009,22(3):82-83
55.王焕亮 张莉等.老年慢性疼痛的评估与治疗.中华现代内科学杂志.2006,3(6):660-661
56.Stanos S,Houle TT.Multidisciplinary and interdisciplinary management of chronic pain.Phys Med Rehabil Clir.N Am.2006,17:435-450
1.姜佐宁.现代精神病学.北京:科学出版社.2004,89-90
2.Delqado PL.Common pathways of depression and pain 「J」.Journal Clin Psychiatry.2004,65(12):16-9
3.Jaracz J,Ryhakowski J.Depression and pain:novel clinical,neurobiological and psychopharmacological data 「J」.Psychiatriapolska.2005,39(5):937-950
4.何梅 贾霞 陈军等.烧伤后并发抑郁患者下丘脑-垂体-肾上腺轴功能变化的研究.中国康复医学杂志.2007,22(12):1120-1121
5.Neeck G,Riedel W.Neurnmediator and hormonal perturhations in fibromyalgia syndrome:results of chronic stress.Baillieres Clin Rheumatol.1994,8(4):763-75
6.Thor KB,Kirby M,Viktrup.Serotonin and noradrenaline involvement in urinary incontinence,depression and pain:scientific basis for overlapping clinical efficacy from a single drug,duloxetine.Int J Clin Pract.2007,61(8):1349-1355
7.王敏建 况利 李大奇.抗抑郁药物对抑郁模型大鼠海马星形胶质细胞的作用.重庆医科大学学报.2006,04
8.Watkins LR,Milligan ED,Mater SF.Spinal cord glia:new players in pain.Pain.2001,93:201-205
9.Krenz NR,Weaver LC.Nerve growth factor in glia and inflammatory cells of the injured rat spinal cord.J Neurochem.2000,74(2):730-739
10.Zerari F,Karpitskiy V,Krause J,et al.Astroglial distribution of neurokinin-2receptor immunoreactivity in the rat spinal cord[J].Neuroseience.1998,84(4):1233-1246.
11.李卉丽 秦绿叶 万有 等.疼痛研究的新亮点:形胶质细胞.生理科学进展.2003,34(1):45-48
12.Ruan HZ,Li X,Li HT.Effects of morphine and electroacupuncture on substance P level in spinal cord and their relation to pain threshod in rats.J Med Coll PIA.1993,8:79-83
13.Cao YQ,Mantyh PW,Carlson EJ,et al.Primary afferent tachykinins are required to experience moderate to intense pain.Nature.1998,392:390-394
14.Bondy B,Bayhai TC,Minovc,et al.Substance Psenum levels are increased in majordepression:preliminary results.J Biol Psychiatry.2003,53:538-542.
15.Ballet S,Aubel B,Mauborgne A,et al.The novel analgesic cizolir-tine inhibitsthe spinal release of substance P and CGRP in rats.Neuropharmacology.2001,40(4):5782-5891
16.Sun RQ,Lawand N,willis WD.The role of calcitonin gene related peptide(CGRP)in the generation and maintenance of mechanical allodynia and hyperalgesiain rates after intradermal injection of capsaicin.Pain.2003,104(122):2012-2081
17.Zhang L,HOff AO,Wiroalawansa SJ,et al.Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity.Pain.2001,89(223):2652-2731
18.Mathe AA,Agren H,Lindstmm L,et al.Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients Apossible trait marker of major depressive disorder.Neurosci Lett.1994,182(2):138-142
19.Jimenez-Vasquez PA,Salmi P,Ahlenius S,et al.Neuropeptide Y in brains of the Flinders Sensitive Line rat a model of depression Effects of electroconvulsivestimuli and damphetamine on peptide concentrations and locomotion.Behav Brain Res.2000,111:115-123
20.Kim H,Whang WW,Kim HT,et al.Expression of neuropeptide Y and cholecystokinin in the rat brain by chronic mild stress.Brain Res.2003,983(122):2012-2018
21.Heilig M,Zachrisson O,Thorsell A,et al.Decreased cerebrospinal fluid NeuropeptideY(NPY) in patients with treatment refractory unipolar majordepression:preliminary evidence for as sociation with prepro NPY genepolymorphism.J Psychialr Res.2004,38(2):1132-121
22.Davidson JR.A history of the concept of atypical depression[J].Clin Psychiatry.2007,68(3):10-5
23.马玲 倪家骧.抗抑郁药物治疗慢性疼痛的研究进展.中国全科医学. 2008,11:2091-2093
24.Matsuzawa-Yanaqida K,Narita M,Nakajima M,et al.Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites[J].Neuropsychopharmacology.2008,33(8):1952-1965
25.Feria M,Abreu P,Abad F,et al.Relationship between autotomy behaviour and spinal cord monoaminergic levels in rats[J].Pain.1992,48(3):429-437
26.Ting E,Roveroni RC,Ferrari LF,et al.Indirect mechanism of histamine-induced nociception in joint of rats[J].Life Science.2007,81(9):765-771
27.朱毅平.米氮平与阿米替林治疗抑郁症并发慢性疼痛的对照研究.医药导报.2008,27(4):408-411
28.魏贤文 李冬雪 徐大斌.慢性疼痛与抑郁障碍的相关性.中国误诊学杂志.2206,6(23):4556-4557
29.Mantyb PW.Neurobiology of substance P and the NKL receptor.J Clin Psychiatry.2002,63(suppl11):6-10
30.Tahmasebi-Sarvestani A,Tedman R,Goss AN.The influence of experimentallyinduced osteoarthrosis on articular nerve fibers of the sheep temporomandibularjoint.J Qrofac Pain.2001,15(3):206-217
31.Datar P,Srivastava S,Coutinho E,et al.Substance P:structure function and therapeutics.Curt Top Med Chem.2004,4:75-103
32.Blier P,Gobbi G,Haddjeri N,et al.Impact of substance P receptor antagonism on the serotonin and norepinephrine systerns:relevance to the antidepressant/anxiolytic response.J Psychiatry Neurosci.2004,9:208-218
33.欧红霞.慢性疼痛和抑郁症临床及生物学相关研究.国际精神病学杂志.2008,35(3):166-169
34.李永华 王永强等.慢性疼痛治疗的循证医学评价,疼痛2004,12(1):28-32